# Clinical Trials Data KIT - Document 42

# Controlled Clinical Trial to Determine the Effective Dose of Cocoa in Lowering Blood Pressure

## Clinical Trial: https://clinicaltrials.gov/study/NCT01276951

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Male\n\* Age: 18 - 65 years old\n\* Resides in Medell\u00edn City\n\* Attached from the contributive regimen of Colombian Health System\n\* Essential Arterial Hypertension, stage I or II.\n\* Be receiving pharmacologic therapy (maximum 2 medications), whose dose has been stable for eight weeks prior to study entry.\n\* Voluntary desire to consume 6,5; 12; 25 or 50 grams of chocolate per day for 18 weeks.\n\* Voluntary desire to participate in the trial and sign informed consent.\n\nExclusion Criteria:\n\n\* Secondary hypertension\n\* Injury in target organ: heart, kidney, brain and retina\n\* Presence of diabetes mellitus\n\* BMI (Body Mass Index) major or equal to 30\n\* Present smoker or with less than four weeks of abstinence of tobacco\n\* Consume antiplatelet substances\n\* Regular consumption of antioxidants and multivitamins\n\* During the study excluded any participant to present a sudden increase in blood pressure: SBP greater than or equal to 180 mmHg and/or DBP greater or equal to 110 mm Hg.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial is focused on the effects of chocolate consumption on blood pressure in patients with essential hypertension. The inclusion/exclusion criteria do \*\*not\*\* mention anything about KIT gene mutations. Therefore, having a KIT gene mutation is neither explicitly inclusive nor exclusive.   
  
A patient with a KIT gene mutation \*could\* be eligible \*\*if\*\* they also meet \*all\* of the other inclusion criteria and \*none\* of the exclusion criteria.